Zaloguj Zarejestruj się zadarmo

Inhibrx organizacji Przychody Q/Q

Jaka jest wartość Przychody Q/Q organizacji Inhibrx?

Wartość Przychody Q/Q organizacji Inhibrx, Inc. to 233.33%

Jaka jest definicja Przychody Q/Q?

Perspektywiczna kwartalna stopa wzrostu z roka (Estimated quarterly EPS growth rate) rok do roku, to szacowany wzrost wartości EPS spółki na następny kwartał w porównaniu do wyników z poprzedniego kwartału.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Przychody Q/Q firm w Health Care sektor na NASDAQ w porównaniu do Inhibrx

Czym się zajmuję organizacja Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy z przychody q/q podobne do Inhibrx